On August 2, 2021 Shanghai Zentera Therapeutics raised $75 million in a Series B financing to support clinical development of its three main cancer drug candidates. In 2020, Zentera was formed by Zentalis Pharma of New York City as a JV for China development of its assets, which target cancer biological pathways (Press release, Zentera Therapeutics, AUG 2, 2021, View Source [SID1234585585]). Zentera will use the proceeds for clinical development and to add new candidates to its portfolio. Founding investors OrbiMed Advisors Asia and Tybourne Capital Management led the B round.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!